Citigroup
SMMT icon

Citigroup’s Summit Therapeutics SMMT Stock Holding History

Citigroup’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$437K Sell
30,000
-120,800
-80% -$2.14M ﹤0.01% 3970
2026
Q1 		$2.86M Buy
+150,800
New +$2.44M ﹤0.01% 2419
2025
Q2 		– Sell
-15,000
Closed -$289K – 5888
2025
Q1 		$289K Buy
+15,000
New +$301K ﹤0.01% 3984

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Citigroup's SMMT Position: Q2 2026 in Review

Citigroup increased its Summit Therapeutics (SMMT) stake by 259% in Q2 2026, buying an estimated $9.13M and bringing the position to 714,000 shares worth $10.4M. The position accounts for ﹤0.01% of the portfolio, ranked #1590.

Citigroup first reported a position in SMMT in Q2 2015 and has held it in 37 quarters since. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • Citigroup held 714,000 shares of Summit Therapeutics worth $10.4M as of Q2 2026.
  • Citigroup bought 514,867 Summit Therapeutics shares in Q2 2026, an estimated $9.13M.
  • Summit Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #1590 holding.
  • Citigroup first reported a position in Summit Therapeutics in Q2 2015 and has held it in 37 quarters since.
  • 242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.